732308-82-6

Basic information

• Product Name: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid
• Synonyms: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid
• CAS NO: 732308-82-6
• Molecular Formula: C₁₃H₁₆O₄
• Molecular Weight: 236.26374
• Mol File: 732308-82-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 371.0±25.0 °C(Predicted)
• Appearance: /
• Density: 1.156±0.06 g/cm3(Predicted)
• PKA: 4.05±0.10(Predicted)
• CAS DataBase Reference: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(732308-82-6)
• EPA Substance Registry System: 2-(4-(tert-butoxycarbonyl)phenyl)acetic acid(732308-82-6)

Safety Data

• Hazardous Substances Data: 732308-82-6(Hazardous Substances Data)

Upstream product

• 918628-81-6 2-(4-tert-butoxycarbonyl-phenyl)-malonic acid dimethyl ester 
• 87524-66-1 4-(methoxycarbonylmethyl)benzoic acid 
• 115-11-7 isobutene 
• 201230-82-2 carbon monoxide 
• 108052-76-2 4-(bromomethyl)benzoic acid 1,1-dimethylethyl ester 
• 59247-47-1 tert-butyl-4-bromobenzoate 
• 934737-91-4 tert-butyl 4-(2-methoxy-2-oxoethyl)benzoate 

Downstream Products

• 1003315-39-6 tert-butyl 4-[2-(4-ethyl-4-oxido-1,4-azaphosphinan-1-yl)-2-oxoethyl]benzoate 
• 149325-40-6 tert-butyl 4-(2-hydroxyethyl)benzoate 
• 936755-34-9 tert-butyl 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoate 
• 936755-32-7 4-{[5-(2-methoxyphenyl)-1,3,4-oxadiazol-2-yl]methyl}benzoic acid 
• 1080060-07-6 tert-butyl 4-{2-[methoxy(methyl)amino]-2-oxoethyl}benzoate 
• 934737-91-4 tert-butyl 4-(2-methoxy-2-oxoethyl)benzoate 
• 936755-33-8 tert-butyl 4-{2-[2-(2-methoxybenzoyl)hydrazin]-2-oxoethyl}benzoate 

Relevant articles and documents

Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530)

A research program to discover solubilizing prodrugs of the HCV NS5A inhibitor pibrentasvir (PIB) identified phosphomethyl analog 2 and trimethyl-lock (TML) prodrug 9. The prodrug moiety is attached to a benzimidazole nitrogen atom via an oxymethyl linkage to allow for rapid and complete release of the drug for absorption following phosphate removal by intestinal alkaline phosphatase. These prodrugs have good hydrolytic stability properties and improved solubility compared to PIB, both in aqueous buffer (pH 7) and FESSIF (pH 5). TML prodrug 9 provided superior in vivo performance, delivering high plasma concentrations of PIB in PK studies conducted in mice, dogs, and monkeys. The improved dissolution properties of these phosphate prodrugs provide them the potential to simplify drug dosage forms for PIB-containing HCV therapy.

ALDOSTERONE SYNTHASE INHIBITORS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein X, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

Inhibitors of Histone Deacetylase

The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.